Robert A. "Bob" Blouin is the Vaughn and Nancy Bryson Distinguished Professor and Dean of the UNC Eshelman School of Pharmacy at the University of North Carolina.

Before coming to UNC in July of 2003, he was a faculty member and administrator at the University of Kentucky College of Pharmacy from 1978 to 2003. Dean Blouin last served as professor and associate dean for research and graduate education from 1997 to 2003 at the UK College of Pharmacy. His responsibilities as associate dean included overseeing the development and expansion of the Center for Pharmaceutical Sciences and Technology, a multimillion-dollar cGMP drug formulation and manufacturing facility. As the executive director of the Office for Economic Development and Innovations Management, he served as the College of Pharmacy representative on all issues external to the University of Kentucky and those relating to economic development of the pharmaceutical sciences. He represented the college on several statewide biotechnology initiatives and has worked to advance faculty-based intellectual property.

Research Interests:
Effects of disease (infectious disease and trauma) on altered physiologic states (i.e., aging and obesity) and the expression and regulation of drug metabolizing enzymes (i.e., cytochrome P450, glucuronosul transferase, and glutathione transferase).

Publications

1. Westerfield BT, Blouin RA:  Ethchlorvynol intoxication.  South Med J. 70:1019-1020, 1977.

2. Bivens BA, Rapp RP, Griffen WO Jr., Blouin RA, Bustrack JA:  Dopamine - phenytoin interaction.  Arch Surg 113:245-249, 1978.

3. Rapp RP, Bustrack JA, Blouin RA:  Dopamine interaction.  Drug Intell Clin Pharm 12:249, 1978.

4. Blouin RA, Mann HJ, Griffen WO Jr., Bauer LA, Record KE:  Tobramycin pharmacokinetics in morbidly obese patients.  Clin Pharmacol Ther 26:508-512, 1979.

5. Bauer LA, Blouin RA, Griffen WO Jr., Record KE, Bell RM:  Amikacin pharmacokinetics in morbidly obese patients.  Am J Hosp Pharm 37:519-522, 1980.

6. Blouin RA, Bauer LA, Piecoro JJ, Holland NH:  Decreased gentamicin half-life during peritoneal dialysis:  A case report.  Drug Intell Clin Pharm 14:218-219, 1980.

7. Blouin RA, Bauer LA, Bustrack JA, Record KE, Bivens BA:  Theophylline hemodialysis clearance.  Ther Drug Monit 2:221-223, 1980.

8. Blouin RA, Elgert JF, Bauer LA:  Theophylline clearance:  effect of marked obesity.  Clin Pharmacol Ther 28:619-623, 1980.

9. Blouin RA, Erwin WG, Dutro MP, Bustrack JA, Rowse KL:  Chloramphenicol hemodialysis clearance. Ther Drug Monitor 2:351-354, 1980.

10. Oeltgen PR, Hamann SR, Blouin RA:  Comparison of gentamicin assays.  Ther Drug Monit 2:423-425, 1980.

11. Bauer LA, Blouin RA:  Influence of age on theophylline clearance in patients with chronic obstructive pulmonary disease.  Clin Pharmacokinet 6:469-474, 1981.

12. Dionne RE, Bauer LA, Gibson GA, Griffen WO Jr., Blouin RA:  Estimating creatinine clearance in morbidly obese patients.  Am J Hosp Pharm 38:841-844, 1981.

13. Lawson LA, Blouin RA, Smith RB, Rapp RP, Young AB:  Phenytoin-dexamethazone interaction: a previously unreported observation.  Surg Neurol 16:23-24, 1981.

14. Bailey RT, Young AB, Rapp RP, Blouin RA:  Theophylline toxicity after the use of aminophylline in the treatment of cerebral vasospasm.  Neurosurgery 9:722-724, 1981.

15. Bauer LA, Blouin RA:  Influence of age on tobramycin pharmacokinetics in patients with normal renal function.  Antimicrob Agents Chemother 20:587-589, 1981.

16. Bauer LA, Bauer SP, Blouin RA:  The effect of acute and chronic renal failure on theophylline clearance.  J Clin Pharmacol 22:65-68, 1982.

17. Lawson LA, Blouin RA, Parker PF:  Quality assurance program for a clinical pharmacokinetic service.  Am J Hosp Pharm 39:607-609, 1982.

18. Blouin RA, Bauer LA, Miller DD, Record KE, Griffen WO Jr.,:  Vancomycin pharmacokinetics in normal and morbidly obese subjects.  Antimicrob Agents Chemother 21:575-580, 1982.

19. Blouin RA, Erwin WG, Foster TS, Scott S:  Pharmacokinetics of theophylline in young and elderly subjects.  Gerontology 28:323-327, 1982.

20. Hamann SR, Oeltgen PR, Shank WA, Blouin RA, Natarajan L:  Evaluation of gentamicin pharmacokinetics during peritoneal dialysis.  Ther Drug Monitor 4:297-300, 1982.

21. Bauer LA, Blouin RA:  Age and phenytoin kinetics in adult epileptics.  Clin Pharmacol Ther 31:301-304, 1982.

22. Bauer LA, Blouin RA:  Gentamicin pharmacokinetics:  Effect of aging in patients with normal renal function.  J Am Geriatr Soc 30:309-311, 1982.

23. Bauer LA, Blouin RA:  Amikacin pharmacokinetics in young men with pneumonia.  Clin Pharm 1:353-355, 1982.

24. Bauer LA, Piecoro JJ, Wilson HD, Blouin RA:  Gentamicin and tobramycin pharmacokinetics in patients with cystic fibrosis.  Clin Pharm 2:262-264, 1983.

25. Bauer LA, Blouin RA:  Influence of age on amikacin pharmacokinetics in patients without renal disease: Comparison with gentamicin and tobramycin.  Eur J Clin Pharmacol 24:639-642, 1983.

26. Benedek IH, Fiske WD, Griffen WO Jr., Bell RM, ,Blouin RA, McNamara PJ:  Serum alpha-1 acid glycoprotein and the binding of drugs in obesity.  Br J Clin Pharmacol 16:751-754, 1983.

27. Bauer LA, Blouin RA:  Phenytoin Michaelis-Menton pharmacokinetics in Caucasian paediatric patients.  Clin Pharmacokinet 8:545-549, 1983.

28. Hamann SR, Blouin RA, McAllister RG:  Clinical pharmacokinetics of verapamil.  Clin Pharmacokinet 9:26-41, 1984.

29. Benedek IH, Blouin RA, McNamara PJ:  Influence of smoking on serum protein composition and the protein binding of drugs.  J Pharm Pharmacol 36:214-216, 1984.

30. Bauer LA, Edwards WA, Randolph FP, Blouin RA:  Cimetidine induced decreases in lidocaine metabolism.  Am Heart J 108:413-415, 1984.

31. Oeltgen PR, Shank WA, Blouin RA, Clark T:  Clinical evaluation of the Abbott TDx(TM) fluorescence polarization immunoassay analyzer.  Ther Drug Monit 6:360-367, 1984.

32. O'Neal W, Whitten KM, Baumann RJ, Blouin RA, Piecoro JJ:  Lack of serious toxicity following carbamazepine overdose.  Clin Pharm 3:545-547, 1984.

33. Brouwer KL, Kostenbauder HB, McNamara PJ, Blouin RA:  Phenobarbital in the genetically obese Zucker rat. I.  Pharmacokinetics after acute and chronic administration.  J Pharmacol Exp Ther 231:649-653, 1984.

34. Brouwer KL, Kostenbauder HB, McNamara PJ, Blouin RB:  Phenobarbital in the genetically obese Zucker rat. II.  In Vivo and In Vitro assessments of microsomal enzyme induction.  J Pharmacol Exp Ther 231:654-659, 1984.

35. Benedek IH, Blouin RA, McNamara PJ:  Serum protein binding and the role of increased alpha 1-acid glycoprotein in moderately obese male subjects.  Br J Clin Pharmacol 18:941-946, 1984.

36. Hamann SR, Blouin RA, Chang SL, Kaltenborn KE, Tan TG, McAllister RG:  Effects of hemodynamic changes on the elimination kinetics of verapamil and nifedipine.  J Pharmacol Exp Ther 231:301-305, 1984.

37. Blouin RA, Brouwer KL, Record KE, Griffen WO Jr., Plezia PM, John W:  Amikacin pharmacokinetics in morbidly obese patients undergoing gastric by-pass surgery.  Clin Pharm 4:70-72, 1985.

38. Hamann SR, Tan TG, Kaltenborn KE, Brouwer KLR, Blouin RA, Chang SL, Vore M, McAllister RG:  Effects of phenobarbital and SKF-525A on In Vitro hepatic metabolism of verapamil and nifedipine.  Pharmacology 30:121-128, 1985.

39. Oeltgen PR, Blouin RA, Spurrier WA, Myers RD:  Hibernation "Trigger" alters renal function in the primate.  Physiol Behav 34:79-81, 1985.

40. McAllister RG, Hamann SR, Blouin RA:  Pharmacokinetics of calcium entry blockers.  Am J Cardiol 55:30B-40B, 1985.

41. Gibson GA, Blouin RA, Bauer LA, Rapp RP, Tibbs PA:  Influence of high dose pentobarbital on theophylline pharmacokinetics: a case report.  Ther Drug Monitor 7:181-184, 1985.

42. Benedek IH, Blouin RA, McNamara PJ:  Altered drug-serum protein binding in the genetically obese Zucker rat.  J Pharm Sci 74:837-840, 1985.

43. Wermeling D, Record K, Bell R, Porter W, Blouin RA:  Hemodialysis clearance of pentobarbital during continuous infusion:  A case report.  Ther Drug Monit 7:485-487, 1985.

44. Michael KA, Mohler JL, Blouin RA, Lucas BA, Rapp RP:  Failure of creatinine clearance to predict gentamicin half-life in a renal transplant patient with diabetes mellitus.  Clin Pharm 4:572-575, 1985.

45. Mohler JL, Barton SD, Blouin RA, Cowen DL, Flanigan RC:  The evaluation of creatinine clearance in spinal cord injured patients.  J Urology 136:366-369, 1986.

46. Fiske WD, Blouin RA, Mitchell B, McNamara PJ:  Renal function in the obese Zucker rat.  Int J Obes 10:175-183, 1986.

47. Wermeling DP, Blouin RA, Porter WH, Rapp RP, Tibbs PA:  Pentobarbital pharmacokinetics in patients with severe head injury.  Drug Intell Clin Pharm 21:459-463, 1987.

48. Huang Chandler MH, Guttendorf RJ, Blouin RA, Wedlund PJ:  Simultaneous quantitation of d- and l-hexobarbital in rat blood by HPLC.  J Chromatogr 419: 426-432, 1987.

49. Blouin RA, Kolpek JH, Mann HJ:  Influence of obesity on drug disposition.  Clin Pharm 6:706-714, 1987.

50. Blouin RA, Dickson P, McNamara PJ, Cibull M, McClain C:  Phenobarbital induction and acetaminophen hepatotoxicity:  resistance in the obese Zucker rodent.  J Pharmacol Exp Ther 243:565-570, 1987.

51. Clifton GD, Blouin RA, Dilea C, Schran HF, Hassell AE, Gonasun LM, Foster TS:  The pharmacokinetics of oral isradipine in normal volunteers.  J Clin Pharmacol 28:36-42, 1988.

52. Chandler MH, Scott SR, Blouin RA:  Age-associated stereoselective alterations in hexobarbital metabolism.  Clin Pharmacol Ther 43:436-441, 1988.

53. McNamara PJ, Blouin RA, Brazzell RK:  The protein binding of phenytoin, propranolol, diazepam and AL01576 (an aldose reductase inhibitor) in human and rat diabetic serum.  Pharm Res 5:261-265, 1988.

54. McNamara PJ, Blouin RA, Brazzell RK:  Serum protein binding of AL01576, a new aldose reductase inhibitor.  Pharm Res 5:319-321, 1988.

55. Chandler MH, Blouin RA:  Theophylline pharmacokinetics in the aged:  A review.  J Geriatric Drug Ther 3:23-40, 1988.

56. Chandler MH, Schran HF, Cutler RE, Smith AJ, Gonasun LM, Blouin RA:  The effects of renal function on the disposition of isradipine.  J Clin Pharmacol 28:1076-1080, 1988.

57. Heintz RC, Ducarre JM, Blouin RA, Guengi A:  Influence of oral dose escalation on the pharmacokinetics of tenoxicam [Tilcotil] in healthy male subjects.  Eur J Rheum Inflam 9-15, 1988.

58. Colangelo P, Chandler M, Blouin R, McNamara P:  Stereoselective binding of propranolol.  Br J Clin Pharmacol 27:519-522, 1989.

59. Blouin RA, Kneer J, Stoeckel K:  Pharmacokinetics of cefetamet (RO15-8074) and oral sefetamet pivoxil (RO15-8075) in young and elderly subjects.  Antimicrob Ag Chemoth 33:291-296, 1989.

60. Foster TS, Kielar RA, Blouin RA, Parr MD, Barton S, Perchak GJ, Johnson JB:  Maintenance of previously controlled intraocular pressure in patients with glaucoma or ocular hypertension:  Comparison of four regimens of methazolamide.  Glaucoma 11:67-71, 1989.

61. Blouin RA, Clifton GD, Adams MA, Foster TS, Flueck J:  Biopharmaceutical comparison of two levothyroxine sodium products.  Clin Pharm 8:588-592, 1989.

62. Kneer J, Tam YK, Blouin RA, Frey FJ, Keller E, Stathakis C, Luginbuehl B, Stoeckel K:  Pharmacokinetics of intravenous cefetamet and oral cefetamet pivoxil in patients with renal insufficiency.  Antimicrob Agents Chemother 33:1952-1957, 1989.

63. Hatton J. Parr MD, Blouin RA:  Estimation of creatinine clearance in patients with Cushing's Syndrome.  Drug Intell Clin Pharm 23:974-976, 1989.

64. Guttendorf RJ, Britto M, Blouin RA, Foster TS, John W, Pittman KA, Wedlund PJ:  Rapid screening for polymorphisms in dextromethorphan and mephenytoin metabolism.  Br J Clin Pharmacol 29:373-380, 1990.

65. McNamara PJ, Blouin RA:  Pharmacokinetic profile of two aromatic retinoids (etretinate and acitretin) in the obese Zucker rats.  J Pharm Sci 79:301-304, 1990.

66. Chandler MH, Clifton GD, Burki NK, Hunt BA, Blouin RA:  Pulmonary function in the elderly: response to theophylline bronchodilation.  J Clin Pharmacol 30:330-335, 1990.

67. Hayton WL, Kneer J, Blouin RA, Stoeckel K:  Pharmacokinetics of intravenous cefetamet and oral cefetamet pivoxil in patients with hepatic cirrhosis.  Antimicrob Agents Chemoth 34:1318-1322, 1990.

68. Schoerlin MP, Blouin RA, Pfefen JP, Guentert TW:  Comparison of the pharmacokinetics of moclobemide in poor and extensive metabolizers of debrisoquine.  Acta Psychiatr Scand Suppl 360:98-100, 1990.

69. Blouin RA, Kneer J, Ambrose RJ, Stoeckel K:  Influence of antacid and ranitidine on the pharmacokinetics of oral cefetamet pivoxil.  Antimicrob Agents Chemoth 34:1744-1748, 1990.

70. Zhang Y, Blouin RA, McNamara PJ, Steinmetz J, Wedlund PJ:  Limitation to the use of the urinary S/R mephenytoin ratio in pharmacogenetic studies.  Br J Clin Pharmacol 31:350-352, 1991.

71. Colangelo P, Rapp R, Blouin R and Kenady D:  Comparative bioavailability and safety of two parenteral vancomycin formulations.  J N Dev Clin Med 8:11-20, 1991.

72. Blouin RA, Cloyd JC, Ludden TM, Kroboth PD:  Central issues relevant to clinical pharmaceutical scientist training programs.  Pharmacotherapy 11:257-263, 1991.

73. Smith DA, Chandler MH, Shedlofsky SI, Wedlund PJ, Blouin RA:  Age-dependent stereoselective increase in the oral clearance of hexobarbitone isomers caused by rifampin.  Br J Clin Pharmacol 32:735-39, 1991.

74. Blouin RA, Hamelin BA, Smith DA, Foster TS, John WJ, Welker HA:  Fleroxacin pharmacokinetics in patients with liver cirrhosis.  Antimicrob Ag Chemoth 36:632-638, 1992.

75. Colangelo PM, Blouin RA, Steinmetz JE, McNamara PJ, Demaria AN, Wedlund PJ:  Age and propranolol stereoselective disposition in humans.  Clin Pharmacol Ther 51:489-494, 1992.

76. Colangelo PM, Blouin RA, Steinmetz JE, McNamara PJ, Demaria AN, Wedlund PJ:  Age and beta-adrenergic receptor sensitivity to S(-)- and R,S(+/-)-propranolol in humans.  Clin Pharmacol Ther 51:549-554, 1992.

77. Hamelin BA, Blouin RA, Wolf KM, Clifton GD, Chandler MH:  In vivo and in vitro beta-2 adrenergic receptor responsiveness in young and elderly asthmatics.  Pharmacotherapy 12:376-382, 1992.

78. Blouin RA, Chaudhary I, Nishihara K, Cox SA:  The effect of liver and renal disease on stereoselective serum binding of flurbiprofen.  Br J Clin Pharmacol 35:62-64, 1993.

79. Blouin RA:  Issues in pharmacotherapy:  Hepatic cytochrome P450 - Application of animal models to therapeutic problems in humans.  The ACCP Report 13:(2),1993.

80.   Israel BC, Blouin RA, McIntyre W, Shedlofsky SI:  Effects of interferon-alpha monotherapy on hepatic drug metabolism in cancer patients.  Br J Clin Pharmacol 36:229-235, 1993.

81. Blouin RA, Bandyopadhyay AM, Chaudhary I, Robertson LW, Gemzik B, Parkinson A:  Cytochrome P450 2B enzyme (CYP2B) induction defect following phenobarbital treatment in the fa/fa rat: Molecular characterization.  Arch Biochem Biophys 303:313-320, 1993.

82. Chaudhary I, Tuntaterdtum S, McNamara PJ, Robertson LW, Blouin RA:  Effect of genetic obesity and phenobarbital treatment on the hepatic conjugation pathways.  J. Pharmacol. Exp. Ther 265:1333-1338, 1993.

83.  Blouin RA, Stoeckel K:  Cefetamet pivoxil clinical pharmacokinetics.  Clin.Pharmacokinet 25:172-188, 1993.

84.  Zannikos PN, Bandyopadhyay AM, Robertson LW, Blouin RA:  Effect of nutritional obesity on the induction of CYP2B enzymes following phenobarbital treatment.  Drug Metab Dispos 21:782-787, 1993

85. Toler SM, Young B, McClain CJ, Shedlofsky SI, Bandyopadhyay AM, Blouin RA:  Head injury and cytochrome P-450 enzymes.  Differential effects on mRNA and protein expression in the Fischer-344 rats.  Drug Metab Dispos 21:1064-1069, 1993.

86. Bandyopadhyay AM, Chaudhary I, Robertson LW, Gemzik B, Parkinson A, Blouin RA:  Expression of a male-specific cytochrome P450 isozyme (CYP2C11) in fa/fa Zucker rats: effect of phenobarbital treatment.  Arch Biochem Biophys 307:386-390, 1993.

87. Tuntaterdtum S, Chaudhary I, Cibull ML, Robertson LA, Blouin RA:  Acetaminophen hepatotoxicity: influence of phenobarbital and ß-naphthoflavone treatment in obese and lean Zucker rats.  Toxicol Appl Pharmacol 123:219-225, 1993.

88. Zannikos PN, Bandyopadhyay AM, Robertson LW, Blouin RA:  Expression of the CYP3A and CYP2C11 enzymes in a nutritionally obese rodent model: response to phenobarbital treatment.  Int J Obes Relat Metab Disord 18:369-374, 1994.

89.  Zannikos PN, Bandyopadhyay AM, Robertson LW, Blouin RA:  Cytochrome P450 2B enzyme induction defect after 2,2’,4,4’,5,5’-hexachlorobiphenyl treatment in the fa/fa Zucker rat.  J Pharmacol Exp Ther 268:1565-1570, 1994.

90.  Blouin RA, McNamara PJ, Chandler MHH, Kostenbauder HB:  Development of a clinical pharmacology program at the University of Kentucky College of Pharmacy.  Am J Pharm Educ 58:289-293, 1994.

91. Shedlofsky SI, Israel BC, McClain CJ, Hill DB, Blouin RA:  Endotoxin administration to humans inhibits hepatic cytochrome P450-mediated drug metabolism.  J Clin Invest 94:2209-2214, 1994.

92.   Chen S, Chou W, Blouin RA, Mao Z, Humphries LL, Meek QC, Neill JR, Martin WL, Hays LR, Wedlund PJ:  The cytochrome P450-2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry.  Clin Pharmacol Ther 60:522-534, 1996.

93.  Roe AL, Blouin RA, Howard G:  In vivo phenobarbital treatment increases protein binding to a putitive AP-1 site in the CYP2B2 promoter.  Biochem Biophys Res Commun 228:110-114, 1996.

94.  Shedlofsky SI, Israel BC, Tosheva R, Blouin RA:  Endotoxin depresses hepatic cytochrome P450-mediated drug metabolism in women.  Br J Clin Pharmacol 43:627-632, 1997.

95.   Rees WA, Harkins JD, Woods WE, Blouin RA, Lu M, Fenger C, Holland RE, Chambers TM, Tobin T:  Amantadine and equine influenza: Pharmacology, pharmacokinetics, and neurological effects in the horse.  Equine Vet J 29(2):104-110, 1997.

96 Roe AL, Howard G, Hou G, Howard G, Shedlofsky S, Blouin RA:  The effect of high dose endotoxin on CYP3A2 expression in the rat.  Pharm Res 15:1603-1608, 1998.

97. Stoeckel K, Hofheinz W, Laneury JP, Duchene P, Shedlofsky SI, Blouin RA:  Stability of cephalosporin prodrug esters in human intestinal juice:  Implications for oral bioavailability.  Antimicrob Agents Chemother 42:2602-2606, 1998.

98. Roe AL, Howard G, Blouin RA:  Characterization of nuclear protein binding (AP-1, GR, and STAT) in the genetically obese (fa/fa) Zucker rat.  Life Sci 63:1339-1346, 1998.

99. Blouin RA, Warren GW:  Pharmacokinetic considerations in obesity.  J. Pharm. Sci 88:1-7, 1999.

100. Roe AL, Howard G, Blouin RA, Snawder JE:  Characterization of cytochrome P450 and glutatione S-transferase activity and expression in male and female ob/ob mice.  Int. J. Obesity 23:48-53, 1999.

101. Watson AM, Warren G, Howard G, Shedlofsky SI, Blouin RA:  Activities of conjugating and antioxidant enzymes following endotoxin exposure.  J Biochem Mol Toxicol 13:63-69, 1999.

102. Warren GW, Poloyac SM, Gary DS, Mattson MP, Blouin RA:  Hepatic cytochrome P-450 expression in the tumor necrosis factor-alpha rceptor (p55/p75) knockout mice after endotoxin administration.  J Pharmacol Exp Ther 288:945-950, 1999.

103.  Blouin RA, Farrell GC, Ioannides C, Renton K, Watlington CO:  Impact of diseases on detoxification.  J Biochem Mol Toxicol 13:215-218, 1999.

104. Watson AM, Poloyac SM, Howard G, Blouin RA:  The effect of leptin on cytochrome P-450, conjugation, and antioxidant enzymes in the ob/ob mouse.  Drug Metab Dispos 27 (6):695-700, 1999.

105. Lu M, Poloyac SM, McNamara PJ, Blouin RA:  The effect of pregnenolone 16 alpha-carbonitrile on the pharmacokinetics and metabolism of dapsone in rats.  J Pharm & Pharmacol 51:803-810, 1999.

106. Rockich K, Blouin RA:  The effect of the acute phase response on the pharmacokinetics of chlorzoxazone and cytochrome P450 2E1 in vitro activity in rats.  Drug Metab Dispos 27:1074-1077, 1999.

107. Rockich K, Hatton J, Kryscio D, Young B, Blouin RA:  Effect of intravenous infusion of rhIGF-1 and daily subcutaneous rhGH and IGFBP-3 levels in brain injury.  Pharmacotherapy 19:1432-1436, 1999.

108. Poloyac SM, Tosheva RT, Shedlofsky SI, Blouin RA:  The effect of endotoxin administration on the pharmacokinetics of chlorzoxazone in humans.  Clin Pharmacol Ther 66:554-562, 1999

109. Poloyac SM, Perez-Rivera AA, Scheff S, Blouin RA:  Tissue specific alterations in the 6-hydroxylation of chlorzoxazone following traumatic brain injury in the rat.  Drug Metab Dispos 29:296-298, 2001.

110. Oakley GG, Roe AL, Blouin RA, Twaroski TP, Ganguly TC, Vore M, Lehmler H-J, Robertson LW:  2,4,4’-Trichlorobiphenyl increases STAT5 transcriptional activity.  Mol Carcinog 30:199-208, 2001.

111. Warren GW, Van Ess P, Watson AM, Mattson MP, Blouin RA:  Cytochrome P450 and antioxidant activity in interleukin-6 knockout mice after induction of the acute phase response.  J Interferon Cytokine Res 21:821-826, 2001.

112. Roe AL, Poloyac SM, Howard G, Shedlofsky SI, Blouin RA:  The effect of endotoxin on hepatic nuclear factor 1 nuclear protein binding: potential implications on CYP2E1 expression in the rat.  J Pharm Pharmacol 53:1365-1371, 2001.

113. Van Ess PJ, Pedersen WA, Culmsee C, Rowley D, Mattson MP, Blouin RA:  Elevated hepatic and depressed renal cytochrome P450 activity in the Tg2576 transgenic mouse model of Alzheimer’s disease. J Neurochem 80: 571-578, 2002.

114. Van Ess PJ, Mattson MP, Blouin RA:  Enhanced induction of cytochrome P450 enzymes and CAR binding in the TNF (p55-/-/p75-/-) double receptor knockout mice following Phenobarbital treatment.  J Pharmacol Exp Ther 300: 824-830, 2002.

115. Van Ess PJ, Poloyac SM, Mattson MP, Blouin RA:  Blunted induction of hepatic CYP in TNF (p55-/-/p75-/-) double receptor knockout mice following clofibrate treatment.  Pharm Res 19:709-713, 2002.

116. Rockich KR, Tosheva R, Cunningham C, Goeger D, Blouin RA, Shedlofsky S:  The effect of endotoxin administration on three putative CYP3A markers in human subjects.  (Submitted).
 

Abstracts/Posters/Presentations

1. Blouin RA:  "Development of a Clinical Pharmacokinetics Drug Monitoring Program", Medical University of South Carolina, Charleston, SC, October 1978 (presentation).

2. Blouin RA:  "Clinical Pharmacokinetics - Concepts in Theophylline Monitoring", Hamot Medical Center, Erie, PA, November 1978 (presentation).

3. Blouin RA:  "Obtaining Third Party Reimbursement for Clinical Services: A Panel Discussion", 13th Annual ASHP Midyear Clinical Meeting, San Antonio, TX, December 1978 (presentation).

4. Blouin RA:  "Rational Use of Drug Blood Levels", Northwestern Society of Hospital Pharmacists, Erie, PA, November 1978 (presentation).

5. Blouin RA:  "Application of Drug Blood Levels in the Clinical Setting", Southeast Kentucky Baptist Hospital Medical Staff Conference, Corbin, KY, January 1979 (presentation).

6. Blouin RA:  "Theophylline Pharmacokinetics", Ohio Society of Hospital Pharmacists Mansfield, OH, June 1979 (presentation).

7. Blouin RA:  "The Pharmacist and the Asthmatic Patient", Kentucky Society of Hospital Pharmacists, Louisville, KY, May 1979 (presentation).
 

8. Blouin RA, Foster TS, Smith RB, and Kostenbauder HB:  "Multidisciplinary Approach Towards the Teaching of Clinical Pharmacokinetics", AACP Annual Meeting, Denver, CO, July 1979 (poster).

9. Blouin RA:  "Aminoglycoside Pharmacokinetics", Morehead Clinic, Morehead, KY, October 1979 (presentation).

10. Dutro MP, Blouin RA, Erwin WG, Bustrack JA, Rowse KL:  "Chloramphenicol Clearance and Protein Binding During Hemodialysis", ASHP Midyear Clinical Meeting, Las Vegas, NV, December 1979 (poster).

11. Dionne RE, Gibson GA, Bauer LA, Blouin RA, and Griffen WO:  "Evaluation of Methods to Estimate Creatinine Clearance in Morbidly Obese Patients", ASHP Midyear Clinical Meeting, Las Vegas, NV, December 1979 (poster).

12. Blouin RA, Bauer LA, Griffen WO., Jr., Record KE, and Bell RM:  "Amikacin Pharmacokinetics in Morbidly Obese Patients", ASHP Midyear Clinical Meeting, Las Vegas, NV, December 1979 (presentation).

13. Blouin RA:  "Theophylline Pharmacokinetics", Hunter Foundation for Health Care, Lexington, KY, May 1980 (presentation).

14. Blouin RA:  "Bioavailability of Drugs and Clinical Pharmacokinetics", The Institute of Applied Pharmaceutical Science, East Brunswick, NJ, July 1980 (presentation).

15. Oeltgen PR, Hamann SR, Blouin RA:  "Comparison of RIA and Emit for the Determination of Serum Gentamicin", American Association for Clinical Chemistry Annual Meeting, Boston, MA, July 1980 (abstract).

16. Bauer LA, Bauer SP, Blouin RA:  "Theophylline Clearance in Cigarette Smoking Patients with Renal Failure", ASHP Midyear Clinical Meeting, San Francisco, CA, December 1980 (poster).

17. Blouin RA:  "How to Develop and Implement a Clinical Pharmacokinetic Service", ASHP Institute, Atlanta, GA, March 1981 (presentation).

18. Blouin RA:  "The Laboratory's Role in Therapeutic Drug Monitoring - Pharmacokinetics in Clinical Practice", University of Kentucky, College of Allied Health Professions, Lexington, KY, May 1981 (presentation).

19.  Blouin RA:  "Acetaminophen Overdose" Medicine Conference, St. Joseph's Hospital, Lexington, KY, October 1981 (presentation).

20. Blouin RA:  "Application of Clinical Pharmacokinetics of Theophylline", Third Annual Open Forum, Toledo, OH, November 1981 (presentation).

21. Blouin RA:  "Development of a Theophylline Pharmacokinetic Service", Fourteenth Annual Expanding Hospital Pharmacy Services Seminar, Toledo, OH, November 1981 (presentation).

22. Rowse KL, Blouin RA, Record KE, Griffen WO, John W:  "Effect of Surgery on the Pharmacokinetics of Amikacin in Morbidly Obese Patients", ASHP Midyear Clinical Meeting, New Orleans, LA, December 1981 (poster).

23. Blouin RA:  "How to Develop and Implement a Clinical Pharmacokinetics Service", ASHP Institute, Cleveland, OH, August 1982 (presentation).

24. Blouin RA:  "Management of the Aged: Pharmacokinetic Considerations" ASHP Midyear Clinical Meeting, Los Angeles, CA, December 1982 (presentation).

25. Bauer LA, Blouin RA:  "Phenytoin Michaelis - Menten Kinetics in Caucasian Pediatric Patients", American Society for Clinical Pharmacology and Therapeutics, San Diego, CA, March 1983 (poster).

26. Fiske WD, Blouin RA, McNamara, PJ:  "P-aminohippurate and Glucose Interaction", APhA Annual Meeting, New Orleans, LA, April 1983 (poster).

27. Benedek IH, Fiske WD, Griffen WO Jr., Blouin RA, McNamara PJ:  "Serum Protein Binding of Drugs and Obesity", APhA Annual Meeting, New Orleans, LA, April 1983 (poster).

28. Rowse KL, Kostenbauder HB, McNamara PJ, Blouin RA:  "Pharmacokinetics of Phenobarbital in Obese Zucker, Lean Zucker and Sprague-Dawley Rats", APhA Annual Meeting, New Orleans, LA, April 1983 (poster).

29. Blouin RA:  "Introduction to Pharmacokinetics", Bristol Laboratories, Syracuse, NY, July 1983 (presentation).

30. Mays-Whitten K, O'Neal W, Piecoro J, Baumann R, Blouin RA:  "Carbamazepine Overdosage: A Case Report", ASHP Midyear Clinical Meeting, Atlanta, GA, December 1983 (poster).

31. Blouin RA:  "Aminoglycoside Antibiotics", Seventeenth Annual Southwestern Clinical Pharmacy Seminar, Tucson, AZ, February 1984 (presentation).

32. Blouin RA:  "Consulting Services and New Technologies", Seventeenth Annual Southwestern Clinical Pharmacy Seminar, Tucson, AZ, February 1984 (presentation).

33. Hamann SR, Blouin RA, Kaltenborn KE, McAllister RG:  "Plasma Level - Dependent Clearance of Verapamil During Intravenous Infusion", American Society for Clinical Pharmacology and Therapeutics, Atlanta, GA, April 1984 (abstract).

34. Rowse Brouwer KL, Kostenbauder HB, McNamara PJ, Blouin RA:  "Hepatic Drug Metabolism in a Genetically Obese Rodent Model: Altered Response to Phenobarbital (Pb) Treatment", FASEB, St. Louis, MO, April 1984 (abstract).

35. Benedek IH, Blouin RA, McNamara PJ:  "Altered Drug Protein Binding in the Serum of a Genetically Obese Zucker Rat", APhA Meeting, Philadelphia, PA, November 1984 (poster).

36. Barton SD, Mohler J, Blouin RA, Rapp RP:  "Creatinine Production in Spinal Cord Injured Patients", OCCP & CP, Cincinnati, OH, November 1984 (poster).

37. Blouin RA:  "Pharmacokinetic Considerations of the Post-Operative and Burned Patient", California Society of Hospital Pharmacists, San Francisco, CA, November 1984 (presentation).

38. Blouin RA:  "Pharmacokinetics Considerations of the Post-Operative and Burned Patient", California Society of Hospital Pharmacists, Los Angeles, CA, November 1984 (presentation).

39. Michael KA, Mohler JL, Blouin RA, Lucas BA, Rapp RP:  "Failure of Creatinine Clearance to Predict Gentamicin Half-Life in a Renal Transplant Patient: A Descriptive Report", ASHP Midyear Clinical Meeting, Dallas, TX, December 1984 (poster).

40. Blouin RA, Fiske WD, McNamara PJ:  "Renal Function in the Genetically Obese Zucker Rat", FASEB, Anaheim, CA, April 1985 (accepted).

41. Blouin RA:  "Renal Function in Obesity - Clinical Implications", Research and Seminar Series, Augusta, GA, February 1985 (presentation).

42. Blouin RA:  "Biopharmaceutic and Pharmacokinetic Considerations of Drug Product Selection", Virginia Society of Hospital Pharmacists, Richmond, VA, November 1985 (presentation).

43. Kolpek J, Blouin RA, Parr M:  "Alteration in Creatinine Production Rates in Cushingoid Patients", ASHP Midyear Clinical Meeting, New Orleans, LA, December 1985 (poster).

44. Foster TS, Blouin RA, Hobbs S, McAllister RG:  "Dose Proportionality of Nifedipine: A Single Escalating Intravenous Dose Study in Man", ACCP, Chicago, IL, July 1986 (poster).

45. Blouin RA, McNamara PJ, Dickson P, McClain C, Cibull M:  "Resistance to Acetaminophen Hepatotoxicity in the Obese Zucker Rodent", AAPS, Washington, DC, November 1986 (poster).

46. Chandler MHH, Guttendorf RJ, Wedlund PJ, Blouin RA:  "Simultaneous Quantitation of d- and l-Hexobarbital in Rat Blood by High Performance Liquid Chromatography", AAPS, Washington, DC, November 1986 (poster).

47. McNamara PJ, Blouin RA, Brazzell RK:  "Drug Protein Binding in Diabetic and Non-Diabetic Serum", AAPS, Washington, DC, November 1986 (poster).

48. McNamara PJ, Blouin RA, Brazzell RK:  "Serum Protein Binding of ALO1576, A New Aldose Reductase Inhibitor", AAPS, Washington, DC, November 1986 (poster).

49. Blouin RA:  Overview of Drug Pharmacology in the Elderly, "Life After Fifty Gerontology Fair", Bowling Green, KY, September 1986 (presentation).

50. Blouin RA:  "Clinical Pharmacokinetic Monitoring: Past, Present and Future", KSHP, Louisville, KY, May 1987 (presentation).

51. Guttendorf RJ, Chandler MHH, Blouin RA, Wedlund PJ:  "Effect of Age on Hexobarbital Stereoselective Disposition in the Rat", AAPS, Boston, MA, June 1987 (poster).

52. Guttendorf RJ, Blouin RA, Foster TS, Wedlund PJ:  "Dextromethorphan Mephenytoin: Influence of Co-Administration on Patient Phenotyping", AAPS, Boston, MA, June 1987 (poster).

53. Chandler MHH, Schran HF, Proskin HM, Gonasun LM, Smith AJ, Foster TS, Hobbs SN, Blouin RA:  "Effects of Renal Function on the Disposition of Isradipine" ACCP, Austin, TX, July 1987 (poster).

54. Blouin RA:  "Clinical Complications in Drug Dosing", Kentucky Academy of Family Physicians, Owensboro, KY, July, 1987 (presentation).

55. Chandler MHH, Scott SC, Blouin RA:  "Age-Dependent Stereoselective Alterations in Hexobarbital Metabolism", American Society of Clinical Pharmacology and Therapeutics, San Diego, CA, March 1988 (poster).

56. Jones P, Chaudhary I, Robertson L, Blouin RA:  "Molecular Basis of Inducibility of cyt P-450 in Obese Rodent Model", Society of Toxicology, Dallas, TX, February 1988 (poster).

57. Chaudhary I, McNamara PJ, Blouin RA:  "Acetaminophen Hepatotoxicity in Obese Zucker Rats: Mechanism of Resistance", Society of Toxicology, Dallas, TX, February 1988 (poster).

58. Blouin RA, Stoeckel K:  "Pharmacokinetic Comparison of Fluoroquinolones", International Congress for Infectious Disease, Rio de Janeiro, April 1988.

59. Kneer J, Blouin R, Keller E, Stathakis C, Stoeckel K:  "Pharmacokinetics of Cefetamet in Patients with Renal Insufficiency", 6th Mediterranean Congress of Chemotherapy, Taormena-Giardini Naxos, Italy, May 1988 (poster).

60. Chaudhary I, McNamara PJ, Blouin RA:  "Effect of Phenobarbital Induction on Acetaminophen Kinetics in Obese Zucker Rat", AAPS, Orlando, FL, November 1988 (poster).

61. Blouin RA, Foster TS, Wedlund PJ, John W, Kolpek J, Robbins D, Cox SR:  "Drug Metabolism of Flurbiprofen Enantiomers in Liver Disease", AAPS, Orlando, FL, November 1988 (poster).

62. Blouin RA:  "Age Related Stereoselective Alterations in Hexobarbital Metabolism", Idaho State University, Pocatello, ID, November 1988 (seminar).

63. Blouin RA:  "Clinical Scientists:  Are They Needed?" Idaho State University, Pocatello, ID, November 1988 (seminar).

64. Chandler MHH, Clifton GD, Blouin RA, Hunt BA, Burki NK:  "Pulmonary Function in Elderly: Response to Theophylline Bronchodilation", ASCPT, Nashville, TN, March 1989 (poster).

65. Chaudhary I, Robertson L, Blouin RA:  "Enzyme Induction Defect to Phenobarbital in the fa/fa Zucker Rat: Relation Between Cytochrome P-450 and UDPGT", SOT, Atlanta GA, March 1989 (poster).

66. Chen LC, Chaudhary I, Blouin RA, Chow CK:  "Effect of Acetaminophen on Hepatic Antioxidant Status of Zucker Rats", FASEB, New Orleans, LA, March 1989 (poster).

67. Smith DA, Chandler MHH, Shedlofsky S, Wedlund PJ, Blouin RA:  "Stereoselective Induction of Hexobarbital with Rifampin", ASCPT, Nashville, TN, March 1989 (poster).

68. Blouin RA:  "Relevance of Animal Models to Human Pharmacokinetics: An Example", ASCPT Symposium on Pharmacokinetics and Pharmacodynamics, Nashville, TN, March 1989 (Symposia presentation).

69. Blouin RA, Smith DA, Chandler MHH, Shedlofsky SI, Wedlund PJ:  "The Effects of Rifampin Treatment on the Stereoselective Metabolism of Hexobarbital in Young and Elderly Subjects", IV World Conference in Clinical Pharmacology & Therapeutics, Heidleberg, Germany, July, 1989 (poster).

70. Blouin RA:  "Stereoisomerism - Practical Considerations", ACCP Symposium on Drug Stereochemistry: What the Science Means to the Clinician, Kansas City, MO, August 1989.

71. Blouin RA:  "Clinical Scientist Program", ACCP, Kansas City, MO, August 1989 (roundtable discussion).

72. Smith DA, Chandler MHH, Shedlofsky SI, Wedlund PJ, Blouin RA:  "The Effects of Rifampin Induction on the Stereoselective Metabolism of Hexobarbital in the Young and Elderly", ACCP, Kansas City, MO, August 1989 (presentation).

73. Foster TS, Blouin RA:  "The Effect of Antacid Timing on Lomefloxacin Bioavailability", Houston, TX, September 1989 (poster).

74. Blouin RA:  "Influence of Obesity on Xenobiotic Metabolism", Ohio Valley Society of Toxicology, Cincinnati, OH, May 1989 (Symposia presentation).

75. Kneer J, Tam YK, Blouin RA, Stoeckel K:  "The Influence of Food and Fluid Intake on the Absorption of Cefetamet Pivoxil", International Congress of Chemotherapy, Jerusalem, Israel, June 1989 (poster).

76. Wedlund PJ, Zhang Y, Britto M, Blouin RA, McNamara PJ, Steinmetz J, DeMaria AN:  "Polymorphic Oxidative Metabolism of S-Mephenytoin", ASCPT, San Fransisco, CA, March 1990 (poster).

77. Colangelo P, Blouin RA, McNamara PJ, Wedlund PJ, Steinmetz J, Demaria AN:  "Age and Its Effect on Propranolol Stereoselective Oral Clearance", ASCPT, San Fransisco, CA, March 1990 (poster).

78. Blouin RA:  "Stereoselective Drug Metabolism", Therapeutics and Pharmacokinetics in the 1990's, Breckenridge, CO, March 1990 (Symposia presentation).

79. Kneer J, Blouin RA, Stoeckel K:  "The Influence of Antacid and Ranitidine Administration on the Pharmacokinetics of Oral Cefetamet Pivoxil", the 7th Mediterranean Congress of Chemotherapy, Barcelona, Spain, May 1990 (poster).

80. Chaudhary I, Parkinson A, Robertson LW, Blouin RA:  "Phenobarbital Induction Defect in the Obese Zucker Rat I", AAPS, Las Vegas, NV, November 1990 (poster).

81. Chaudhary I, Parkinson A, Robertson LW, Blouin RA:  "Phenobarbital Induction Defect in the Obese Zucker Rat II", AAPS, Las Vegas, NV, November 1990 (poster).

82. Chaudhary I, Nishihara, K, Robertson LW, Blouin RA:  "Phenobarbital Induction Defect in the Obese     Zucker Rat III", AAPS, Las Vegas, NV, November 1990 (poster).

83. Chaudhary I, Nishihara K, Robertson LW, Blouin RA:  "PCB Induction Defect in the Obese Zucker Rat", AAPS, Las Vegas, NV, November 1990 (poster).

84. Hallak HO, Wedlund PJ, Foster TS, Blouin RA, John W, Patel IH:  "Midazolam Disposition and Response in Efficient and Poor Metabolizers of Dextromethorphan", ASCPT, San Antonio, TX, March 1991 (poster).

85. Blouin RA:  "Phenobarbital in the Genetically Obese Zucker Rat: Differential Induction of Gene Expression", Wayne State University, Detroit, MI, October 1990 (presentation).

86. Blouin RA, Bandyopadhyay AM, Chaudhary I:  "Effect of Phenobarbital Treatment on Cytochrome P-450IIC11 mRNA in Obese Zucker Rats", FASEB, Atlanta, GA, April 1991 (poster).

87. Bandyopadhyay AM, Chaudhary I, Blouin RA:  "Molecular Mechanism of Phenobarbital Induction Defect of Cytochrome P-450IIB1/IIB2 in Obese Zucker Rats", FASEB, Atlanta, GA, April 1991 (poster).

88. Chaudhary I, Tuntaterdtum S, Cibull ML, Blouin RA:  "Effect of P-450 Inducers on Acetaminophen Hepatotoxicity in Obese Zucker Rats", FASEB, Atlanta, GA, April 1991 (poster).

89. Chandler MHH, Hamelin BA, Clifton GD, Blouin RA, Wolf KM:  "Terbutaline Pharmacodynamics in Young and Elderly Asthmatics", ACCP, Minneapolis, MN, August 1991 (poster).

90.  Chandler MHH, Hamelin BA, Blouin RA, Clifton GD, Wolf KM:  "Responsiveness of Pure T-Lymphocytes to a Beta-2 Agonist in Young and Elderly Asthmatics", ACCP, Minneapolis, MN, August 1991 (poster).

91. Blouin RA:  "Central Issues Relevant to Clinical Pharmaceutical Scientist Training Programs", ACCP, Minneapolis, MN, August 1991 (presentation).

92. Nishihara K, Chaudhary K, Cox S, Blouin RA:  "Stereoselective Protein Binding of Flurbiprofen in Liver and Renal Disease", AAPS, Washington, DC, November 1991 (poster).

93.  Colangelo PM, Blouin RA, Steinmetz JE, McNamara PJ, Wedlund PJ:  "Effect of Age on Propranolol Stereoselective Disposition in Man", AAPS, Washington, DC, November 1991 (poster).

94. Colangelo PM, Blouin RA, Steinmetz JE, McNamara PJ, Wedlund PJ:  "Effect of Age on Propranolol Enantiomer Pharmacodynamics in Man", AAPS, Washington, DC, November 1991 (poster).

95. Blouin RA:  "Management of Drugs in the Elderly", University of Cincinnati Medical Center Geriatrics/Gerontology Speaking Series, Cincinnati, OH, October 1991 (presentation).

96. Blouin RA:  "Stereoselective Drug Metabolism in the Elderly: Pharmacodynamic Considerations", University of Cincinnati, College of Pharmacy, Cincinnati, OH, October 1991 (presentation).

97. Blouin RA:  "Obtaining Peer Reviewed Funding:  Critical Issues for Young Investigators”, ACCP Winter Meeting, Phoenix, AZ, February 1992 (presentation).

98. Blouin RA:  "Factors Influencing the Regulation and Expression of Hepatic Cytochrome P450 2B Enzymes", 1992 AAPS Southeastern Regional Meeting, Wilmington, NC, April 1992 (Symposia presentation).

99. Bandyopadhyay A, Blouin RA:  "Phenobarbital Induction Defect of Cytochrome P450 2B1/2B2 in Obese Zucker Rat in Hepatocyte Culture", FASEB, Anaheim, CA, April 1992 (poster).

100. Toler SM, Young BA, Bandyopadhyay A, Blouin RA:  "The Effect of Head Trauma on Hepatic Cytochrome P-450 in the Fisher-344 Rat", AAPS 1992 Southeast Regional Meeting, Wilmington, NC, April 1992 (poster).

101. Zannikos PN, Bandyopadhyay A, Blouin RA:  "Effect of Chronic High Fat Diet on the Expression/Regulation of the Hepatic Cytochrome P-450 System", AAPS 1992 Southeast Regional Meeting, Wilmington, NC, April 1992 (poster).

102. Israel BC, Shedlofsky SI, Swim A, Blouin RA:  "Decreased Theophylline and Antipyrine Clearance in Cancer Patients Treated with Interferon-A (IFN)", ACCP, Toronto, Canada, August 1992 (poster).

103. Toler SM, Young BA, Bandyopadhyay A, Blouin RA:  "The Effect of Head Trauma on Hepatic CYP3A and CYP2C11 in the Fisher-344 Rat", 1992 Midwest Cytochrome P450 Symposium, Lafayette, IN, September 1992 (poster).

104. Zannikos PN, Bandyopadhyay A, Blouin RA:  "Effect of Chronic High Fat Diet on the Expression/Regulation of the Hepatic CYP2B1/2B2", 1992 Midwest Cytochrome P450 Symposium, Lafayette, IN, September 1992 (poster).

105.  Blouin RA, Bandyopadhyay A, Chaudhary I, Robertson LW, Gemzick B, Parkinson A:  "CYP2B Enzyme Induction Defect: Molecular Characterization”, 1992 Midwest Cytochrome P450 Symposium, Lafayette, IN, September 1992 (poster).

106.  Israel BC, Shedlofsky SI, Swim A, Blouin RA:  Effects of Endotoxin Induced Sepsis on Cytochrome P-450 Drug Metabolism”, ACCP Annual Meeting, Reno, NV, August 1993 (presentation).

107.  Blouin RA:  "Stereoselective Drug Metabolism”, Fourth International Symposium on Chiral Discrimination, Montreal, Quebec, September 1993 (Symposia presentation).

108.  Zannikos PN, Bandyopadhyay AM, Robertson LW, Blouin RA:  "CYP2B Enzyme Induction following Treatment with 2,2’,4,4’,5,5’- Hexachlorobiphenyl in the obese Zucker rat”, AAPS, Orlando, FL, November 1993 (poster).

109. Nishihara KK, McNamara PJ, Blouin RA:  "Expression of CYP2B Enzymes: Comparison of Concentration-Response Relationships in Young & Adult Rats”, AAPS, Orlando, FL, November 1993 (poster).

110. Ma Li, Cohen DA, Blouin RA:  "The Effect of Murine Acquired Immunodeficiency Syndrome (MAIDS) on Hepatic Microsomal Steroid Hydroxylase Activities”, AAPS, Orlando, FL, November 1993 (poster).

111. Shedlofsky SI, Israel BC, Swim AT, Denison MG, Hill DB, McClain CJ, Blouin RA:  "Decreased Hepatic P450-Mediated Drug Clearances in Humans Given Endotoxin (LPS) as a Model of Gram-Negative Sepsis”, AASLD, Chicago, IL, November 1993 (poster).

112. Blouin RA:  "Research in Clinical Sciences”, 11th Annual Merrillville Symposium on Pharmaceutical Sciences Graduates Programs, Merrillville, IN, October 1993 (Symposia presentation).

113. Israel BC, Shedlofsky SI, Blouin RA:  "Evaluation of an Animal Model of Sepsis:  Effect on Hepatic P450 Expression”, ACCP Annual Meeting, St. Louis, MO, August 1994 (poster).

114.  Blouin RA:  "Mechanism(s) of Phenobarbital Induction: Applications of a Mutant Rodent Model”, University of Alberta, Edmondton, Alberta, April 1994 (presentation).

115.  Roe AL, Howard G, Blouin RA:  "The Effect of Acute and Chronic In Vivo Phenobarbital Treatment on DNA Binding Proteins”, 10th International Symposium on Microsomes & Drug Oxidation, Toronto, Ontario, July 1994 (poster).

116.  Young B, McClain CJ, Kindy M, Dempsey R, Blouin R, Gillespie M, Scheff S:  "Pneumatic Impacter Model of Head Injury Simulates Metabolic Aspects of Head Injury”, Congress of Neurosurgical Surgeons, Chicago, IL, October 1994.

117.  Roe AL, Howard G, Blouin RA:  "Acute and Chronic In Vivo Phenobarbital Treatment Effects on GRE and AP-1 DNA Binding Proteins”, SOT 1995 Annual Meeting, Baltimore, MD, March 1995 (poster).

118. Boni J, Chaudhary I, Batastini G, Tonelli A, Woolcock I, DiStefano F, Vella A, Blouin R, Parkinson A, Eldridge S, Davis H:  "A Toxicokinetic and Mechanistic Toxicity Study of CL275,838 (A Novel Memory Enhancing Agent) after Subchronic Dosing in Rats”, AAPS, Miami, Fl, November 1995 (poster).

119.  Rees WA, Chambers T, Fenger C, Harkins JD, Blouin RA, Holland R, Tobin T:  "The Pharmacokinetics and Bioavailability of Amantidine in the Horse:  A Preliminary Report”, Am Assoc Equine Prac. 1995.

120.  Blouin RA and Wedlund PJ:  "Pharmacokinetics for the Pharmaceutical Scientist:  A Short Course”, F. Hoffmann LaRoche, Nutly, NJ, July 1995 (presentation).

121. Blouin RA:  "Joint Pharm.D./Ph.D. Programs”, AACP Annual Meeting, Philadelphia, PA, July 1995 (presentation).

122.  Israel BC, Shedlofsky SI, Tosheva R, Blouin RA:  "Endotoxin Differentially Inhibits Hepatic Cytochrome P450 Drug Metabolism in Female Volunteers”, ACCP Annual Meeting, Washington, DC, August 1995 (presentation).

123.  Blouin RA:  "Obese Zucker Rodent Model: Responsiveness to Phenobarbital Induction”, 1995 Midwest Cytochromes P450 Symposium, Purdue University, West  Lafayette, IN, September 1995 (presentation).

124.  Roe AL, Howard G, Shedlofsky SI, Blouin RA:  "Cytokine Regulation of CYP3A2 Expression in Rats Treated with LPS”, SOT 1996 Annual Meeting, Anaheim, CA, March 1996 (poster).

125. Lu M, Blouin RA:  "Evaluation of Formation Clearance of Dapsone Hydroxylamine as a Marker of CYP3A Activity:  An In Vivo and In Vitro Correlation”, AAPS 1996 Annual Meeting, Seattle, WA, October 1996 (presentation).

126. Blouin RA:  "Obese Rodent Models: Alterations in Gene Expression of Drug Metabolizing Enzymes”, 1996 Annual Mini-Symposium in Nutritional Sciences, Lexington, KY, April 1996 (presentation).

127.  Roe AL, Howard G, Shedlofsky S, Blouin RA:  "The Effect of High Dose Endotoxin on Nuclear Protein Binding: Implications on CYP3A2 Regulation”, 1996 Midwest Cytochromes P450 Symposium, Purdue University, West Lafayette, IN, September 1996 (poster).

128.  Warren G, Roe AL, Hou J, Shedlofsky S, Blouin RA:  "The Effect of High Dose Endotoxin on Hepatic CYP3A2 Regulation”, 1996 Midwest Cytochromes P450 Symposium, Purdue University, West Lafayette, IN, September 1996 (poster).

129. Lu M, Blouin RA:  "The Effect of Pregnenolone 16a-Carbonitrile on the Pharmacokinetics and Metabolism of Dapsone”, 1996 Midwest Cytochromes P450 Symposium, Purdue University, West Lafayette, IN, September 1996 (poster).

130.  Blouin RA:  "The Effect of Head Trauma/Acute Phase Response on Brain and Liver Cytochrome P450 Enzymes”, The Second Annual Kentucky Spinal Cord and Brain Injury Trust Symposium 1996, Lexington, KY, June 1996 (presentation).

131.  Lu M, Poloyac SM, Blouin RA:  "Evaluation of Oxidation of Dapsone as a Marker of CYP3A Activity: An In Vivo and In Vitro Correlation”, SOT 1997 Annual Meeting, Cincinnati, OH March 1997 (poster).

132.  Warren G, Roe AL, Hou J, Shedlofsky S, Blouin RA:  "The Effect of High Dose Endotoxin on CYP3A Expression”, SOT 1997 Annual Meeting, Cincinnati, OH March 1997 (poster).

133.  Roe AL, Howard G, Shedlofsky S, Blouin RA:  "The Effect of High Dose Endotoxin on Nuclear Protein Binding: Implications on CYP3A2 Regulation”, SOT 1997 Annual Meeting, Cincinnati, OH, March 1997 (poster).

134.  Blouin RA:  "Special Pharmacokinetic Considerations in the Obese Patient”, APhA Annual Meeting, Los Angeles, CA, March 1997 (Symposia presentation).

135.  Watson A, Howard G, Shedlofsky S, Blouin RA:  "Changes in Conjugation and Antioxidant Enzymes following Endotoxin Exposure”, IUBMB, San Francisco, CA, August 1997 (poster).

136.  Roe A, Howard G, Blouin RA:  "Constitutive AP-1 Binding Activity in the Genetically Obese (fa/fa) Zucker Rat”, IUBMB, San Francisco, CA, August 1997 (poster).

137.  Roe A, Poloyac S, Howard G, Shedlofsky S, Blouin RA:  "The Effect of High Dose Endotoxin on Hepatic CYP2E1 Regulation and Expression”, IUBMB, San Francisco, CA, August 1997 (poster).

138. Rockich K, Hatton J, Kryscio R, Young B, Blouin RA:  "The effect of Continuous Intravenous Infusion of rhIGF-1 and Daily Subcutaneous Administration of rhGH on IGF-1 and IGFBP-3 Plasma Concentrations in Traumatic Brain Injured Patients”, AAPS, Boston, MA, November 1997 (poster).

139. Oakley GG, Roe AL, Blouin RA, Ganguly T, Vore M, Robertson W:  "Activation of AP-1 and STAT Transcription Factors by Non-Coplanar Polychlorinated Biphenyls”, SOT, Seattle, WA, March 1998 (poster).

140. Blouin RA:  "Expression and Regulation of Xenobiotic-Metabolizing Enzymes in Obesity”, 12th International Symposium on Microsomes and Drug Oxidations, Montpellier, France, July 1998 (Symposia presentation).

141.  Blouin RA:  "The Effect of Head Trauma/Acute Phase Response on Brain and Liver Cytochrome P450 Enzymes”, 4th Annual Kentucky Spinal Cord and Head Injury Research Symposium, Lexington, KY, July 1998 (presentation).

142.  Rockich K, Blouin RA:  "The Effect of the Acute Phase Response on Chlorzoxazone Pharmacokinetics and CYP2E1 Activity in the Rat”, ACCP 1998 Annual Meeting, Cincinnati, OH, November 1998 (poster).

143.  Blouin RA:  "Relating In-Vitro Data to In-Vivo Drug Interactions”, ACCP 1998 Annual Meeting, Cincinnati, OH, November 1998 (Symposia presentation).

144.  Blouin RA:  "Translational Research with Drug Interactions”, ACCP 1998 Annual Meeting, Cincinnati, OH, November 1998 (Symposia presentation).

145. Warren G, Mattson M, Blouin RA: "Hepatic Cytochrome P450 Expression in IL-6 Knockout Mice following Endotoxin Administration”, SOT 1999 Annual Meeting, New Orleans, LA, March 1999 (poster).

146. Roe AL, Warren G, Mattson M, Blouin RA:  "AP-1 Binding Activity Is Altered in LPS-Treated TNF a (p55/p75) Double Receptor Knockout Mice”, SOT 1999 Annual Meeting, New Orleans, LA, March 1999 (poster).

147. Gardner BM, Poloyac SM, Shedlofsky SI, Blouin RA:  “Serum Protein Binding of Chlorzoxazone in Human:  The Effect of Endotoxin Administration”, ASHP 1998 Annual Meeting, Las Vegas, NV, December 1998 (poster).

148. Poloyac SM, Tosheva T, RT, Shedlofsky SI, Blouin RA:  “Variable Changes in CYP2E1 Activity after Endotoxin Administration in Humans”, SOT 1999 Annual Meeting, New Orleans, LA, March 1999 (poster).

149. Blouin RA:  “Post-Graduate Education”, University of Minnesota Seminar Series, Minneapolis, MN, March 1999 (Presentation).

150. Blouin RA:  “Prediction Drug-Drug Interactions from In-Vitro Data”, University of Minnesota College of Pharmacy Seminar Series, Minneapolis, MN, March 1999 (Presentation).

151. Van Ess PJ, Pedersen WA, Culmsee C, Mattson MP, Blouin RA:  “Alterations in Cytochrome P450 Enzyme Activity in Transgenic Mice Expressing Familial Alzheimer’s Disease-Linked Mutant Beta Amyloid Precursor Protein”, AAPS 1999 Annual Meeting, New Orleans, LA, November 1999 (poster).

152. Poloyac SM, Blouin RA:  “Tissues Specific Alterations in CYP2E1 Expression following Traumatic Brain Injury in the Rat”, AAPS 1999 Annual Meeting, New Orleans, LA, November 1999 (poster).

153. Rockich KT, Tosheva T, RT, Shedlofsky SI, Blouin RA:  “The Effect of Endotoxin Administration on CYP3A4 Activity in Humans”, AAPS 1999 Annual Meeting, New Orleans, LA, November 1999 (poster).

154. Blouin RA, DiPiro JT, Evans WE, Fletcher CV, Johnson JA, Relling MV:  “Establishing the Link:  Developing Proposals that Fill a Gap in Knowledge - Mock Study Section: Critique of Contemplated Methods”, 1999 ACCP Annual Meeting, Kansas City, MO, October 1999 (Symposia presentation).

155. Blouin RA:  “Understanding Changes in Hepatic Drug Metabolism through Pharmacokinetic Data Analysis of Model Probe Drugs”, 1999 Conference on Nonlinear Statistical Models:  Implementation and Application, Lexington, KY, November 1999 (Symposia presentation).

156. Shedlofsky SI, Tosheva RT, Rockich KT, Cunningham CR, Goeger DE, Blouin RA:  “Superiority of Midazolam as a Probe for Assessing CYP3A4 Activity in Human Endotoxin Model”, SOT 2000 Annual Meeting, Nashville, TN, March 2000 (poster).

157. Blouin RA:  “Expression and Regulation of Drug Metabolizing Enzymes in Obesity”, ASBMB/ASPET Annual Meeting, Boston, MA, June 2000 (Symposia presentation).

158. Lubawy WC, Yokel RA, Blouin RA, Blumenschein K:  “Advanced Degree Programs Integrated with the Doctor of Pharmacy Curriculum as a Foundation for the Future”, AACP Annual Meeting, San Diego, CA, July 2000 (poster).

159. Van Ess PJ, Warren GW, Mattson MP, Blouin RA:  “Effect of Clofibrate Administration on Cytochrome P450 Activity in TNF p55/p75 Double Receptor Knockout Mice”, AAPS Annual Meeting, Indianapolis, IN, November 2000 (poster).

160. Van Ess PJ, Warren GW, Mattson MP, Blouin RA:  “Enhanced Phenobarbital Induction of Hepatic CYP2B Parallels CAR Activation in Tumor Necrosis Receptor Double Knockout Mice”, AAPS Annual Meeting, Denver, CO, November 2001 (poster).

161. Blouin RA (panel member):  “Promoting German, Austrian, and Swiss Investment in Kentucky”, Kentucky German Business Council 2nd Annual Conference, Lexington, KY October 2001.

162. Van Ess PJ, Warren GW, Mattson  MP, Blouin RA:  “Effect of Phenobarbital on Cytochrome P450 Induction in Tumor Necrosis Factor and Interleukin-6 Defficient Mice”, 33rd Annual Pharmaceutical Graduate Student Research Meeting, Madison, WI, July 2001 (Dr. Van Ess received 2nd place poster presentation award for this work).

163. Tosheva RT, Van Ess P, Cunningham CR, Blouin RA, Shedlofsky SI:  “Increased CYP2E1 Activity and Enhanced Systemic Oxidative Stress after Endotoxin in Humans”, SOT Annual Meeting, Nashville, TN, March 2002.

164. Van Ess P, Charriez C, Tosheva RT, Shedlofsky SI, Blouin RA:  “Correlation between NFkB and Changes in Chlorzoxazone Disposition following an Acute Phase Response”, 2002 ACCP Spring Practice and Research Forum, Savannah, GA, April 2002 (poster).

165. Blouin RA:  “The Impact of Obesity on Drug Pharmacokinetics and Pharmacodynamics”, 2002 ACCP Spring Practice and Research Forum, Savannah, GA, April 2002 (presentation).

166. Blouin RA:  “The Effect of the Acute Phase Response on CYP2E1 Expression and Regulation”, Department of Medicinal Chemistry Seminar Series, The Ohio State University, Columbus, OH, April 2002 (presentation).

167. Blouin RA:  “Effect of Obesity on Drug Metabolism”, University of Kentucky Center for Nutritional Sciences Seminar Series, Lexington, KY April 2002 (presentation).